OBSV Key Statistics, Chart & Performance
The current stock price of OBSV is 0.1018 USD. In the past month the price decreased by -41.8%. In the past year, price decreased by -92.4%.
OBSV Technical Analysis
OBSV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OBSV. OBSV has a bad profitability rating. Also its financial health evaluation is rather negative.
OBSV Financial Highlights
Over the last trailing twelve months OBSV reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by 6.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OBSV Forecast & Estimates
7 analysts have analysed OBSV and the average price target is 12.24 USD. This implies a price increase of 11923.58% is expected in the next year compared to the current price of 0.1018.
For the next year, analysts expect an EPS growth of 12.85% and a revenue growth -33.03% for OBSV
OBSV Ownership
About OBSV
Company Profile
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 51 full-time employees. The company went IPO on 2018-07-13. The firm develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and uterine fibroids; Nolasiban (OBE001), an oral oxytocin receptor antagonist, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor.
Company Info
OBSEVA SA
Chemin des Aulx 12
Plan-les-Ouates GENEVE 1228 CH
CEO: Brian O'Callaghan
Employees: 51
Phone: 41225521558.0
OBSEVA SA / OBSV FAQ
Can you describe the business of OBSEVA SA?
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 51 full-time employees. The company went IPO on 2018-07-13. The firm develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and uterine fibroids; Nolasiban (OBE001), an oral oxytocin receptor antagonist, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor.
Can you provide the latest stock price for OBSEVA SA?
The current stock price of OBSV is 0.1018 USD. The price decreased by -15.52% in the last trading session.
Does OBSV stock pay dividends?
OBSV does not pay a dividend.
How is the ChartMill rating for OBSEVA SA?
OBSV has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for OBSV stock?
The Revenue of OBSEVA SA (OBSV) is expected to decline by -33.03% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for OBSV stock?
You can find the ownership structure of OBSEVA SA (OBSV) on the Ownership tab.